You searched for "intracameral"
Insights in resistant diabetic macular oedema
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...
Intravitreal Bevacizumab for the prevention of postoperative proliferative vitreoretinopathy in high-risk patients
This single- centre observational retrospective study was conducted to evaluate the effect of intravitreal injection of bevacizumab at the time surgery for rhegmatogenous retinal detachment (RRD) repair on postoperative proliferative vitreoretinopathy (PVR) in patients at high risk selected by laser...
Autofluorescence patterns in subretinal haemorrhages associated with neovascular age-related macular degeneration
The aim of this retrospective study was to describe the surgical results and fundus autofluorescence (FAF) patterns occurring in sub-macular haemorrhage (SMH) of duration <60 days in age-related macular degeneration (AMD). Notes from 39 eyes of 39 patients with SMH,...
IVTA for diabetic macular edema and macular edema secondary to retinal vein occlusion: a meta-analysis
This meta-analysis aimed to compare the safety and efficacy of different doses of intravitreal triamcinolone acetonide (IVTA) for diabetic macular oedema (DME) and macular oedema (ME) secondary to retinal vein occlusion (RVO). A systematic literature search for randomised controlled trials...Oct/Nov 2019 Quiz
History A 62-year-old female patient was referred for rapid growth of a left periorbital soft tissue lesion with proptosis. Her past medical history included: hypertension, hyperlipidaemia and bipolar disorder. On examination: vision in the affected eye was hand movements, right...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
